Summary
Late-breaking results from a phase 3, randomized, double-blind, multicenter study provide convincing evidence that RAD001 is a safe and effective treatment for patients with metastatic renal cell carcinoma and validate mTOR inhibition as a cancer treatment.
- Gastrointestinal Cancers Clinical Trials
- © 2008 MD Conference Express
Tools
Trial Results Establish Clinical Benefit of RAD001 in Advanced Renal Cell Carcinoma
Permalink:
Table of contents
Cited By...
- No citing articles found.